As of May 10, 2021, Stark & Stark is no longer accepting inquiries for this litigation. For an updated list of our current cases, visit our homepage.
What is Pradaxa?
Pradaxa (dabigatran etexilate) is an FDA-approved blood thinner prescribed to patients to control atrial fibrillation (irregular heartbeat), deep vein thrombosis (DVT) and pulmonary embolus (PE).
Pradaxa has been widely prescribed, with millions of people taking the medication since it entered the market. Pradaxa is manufactured by Boehringer Ingelheim. Marketing efforts claim that Pradaxa is safer than warfarin (a traditional anticoagulant), but recent studies suggest otherwise.
Pradaxa Injuries, Side Effects, and Lawsuits
Since its approval, there have been numerous reports of increased risk of uncontrollable bleeding and injury when taking Pradaxa, including: gastrointestinal (GI) bleeding, intracranial bleeding, hemorrhagic stroke, and, in some cases, death.
Thousands of claims against the makers of Pradaxa were consolidated into a Multidistrict Litigation (MDL) in the United States District Court for the Southern District of Illinois. In 2014, Boehringer Ingelheim settled roughly 4,000 of those claims for $650 million. Lawsuits are still moving forward in courts throughout the nation.
Are you impacted by Pradaxa? Contact a Pradaxa lawsuit lawyer today to discuss your claim.
Stark & Stark’s Mass Tort team pursues claims against drug manufacturers so they can be held liable when the drugs they market are proven to be defective and cause injury to the people who use them. Our Pradaxa lawsuit lawyers are experienced in mass torts MDL litigation cases and in negotiating with pharmaceutical settlement representatives. If you or a member of your family has suffered an injury from Pradaxa use, you may be entitled to compensation.
Please contact Stark & Stark to speak with one of the Pradaxa attorneys, free of charge, who can help assess any claims that you may have and to help you understand the settlement and lawsuit process.